Condition
Non-hematologic Malignancies
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Completed2
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01705483Phase 1Terminated
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
NCT00526617Phase 1CompletedPrimary
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
NCT01454076Phase 1CompletedPrimary
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
NCT00641160Phase 1UnknownPrimary
Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies
Showing all 4 trials